Gastric carcinoma

Current Oncology Reports

Volumn 6, Issue 3, 2004, Pages 192-198

  Phan, Alexandria T ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CISPLATIN; CYTARABINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; LOMUSTINE; METHOTREXATE; MITOMYCIN; PACLITAXEL; TEGAFUR; UFT;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; PATIENT CARE; POSTOPERATIVE COMPLICATION; REVIEW; STOMACH CARCINOMA; SURGICAL MORTALITY; UNITED STATES; WESTERN HEMISPHERE;

EID: 3042719211     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0049-7     Document Type: Review

References (59)

1. American Cancer Society: 2004 Cancer Statistics. ACS: Philadelphia; 2004.
2. Fuchs CS, Mayer RJ: Gastric carcinoma. N Engl J Med 1995, 333:32-41.
3. Wiggins CL, Becker TM, Key CR, Samet JM: Stomach cancer among New Mexico's American Indians, Hispanic whites, and non-Hispanic whites. Cancer Res 1989, 49:1595-1599.
4. Powell J, McConkey CC: Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1990, 62:440-443.
5. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991, 265:1287-1289.
6. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001, 49:347-353.
7. Rhyu MG, Park WS, Jung YJ, et al.: Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. Gastroenterology 1994, 106:1584-1588.
8. Becker KF, Atkinson MJ, Reich U, et al.: E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994, 54:3845-3852.
9. Yoshida T, Sakamoto H, Terada M: Amplified genes in cancer in upper digestive tract. Semin Cancer Biol 1993, 4:33-40.
10. Dooley CP, Larson AW, Stace NH, et al.: Double-contrast barium meal and upper gastrointestinal endoscopy: a comparative study. Ann Intern Med 1984, 101:538-545.
11. Longo WE, Zucker KA, Zdon MJ, Modlin IM: Detection of early gastric cancer in an aggressive endoscopy unit. Am Surg 1989, 55:100-104.
12. Graham DY, Schwartz JT, Cain GD, Gyorkey F: Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology 1982, 82:228-231.
13. Greene F, Page D, Fleming I, eds: American Joint Committee on Cancer (AJCC) Cancer Staging Manual, edn 6. New York: Springer-Verlag; 2002.
14. Pollack BJ, Chak A, Sivak MV Jr: Endoscopic ultrasonography. Semin Oncol 1996, 23:336-346.
15. Ott K, Sendler A, Becker K, et al.: Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 2003, 6:159-167.
16. Conlon KC, Karpeh MS Jr: Laparoscopy and laparoscopic ultrasound in the staging of gastric cancer. Semin Oncol 1996, 23:347-351.
17. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
18. Wanebo HJ, Kennedy BJ, Chmiel J, et al.: Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg 1993, 218:583-592.
19. Noguchi Y, Imada T, Matsumoto A, et al.: Radical surgery for gastric cancer: a review of the Japanese experience. Cancer 1989, 64:2053-2062.
20. Cuschieri A, Fayers P, Fielding J, et al.: Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996. 347:995-999.
21. Bonenkamp JJ, Hermans J, Sasako M, et al.: Extended lymphnode dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med 1999, 340:908-914.
22. Karpeh MS, Leon L, Klimstra D, Brennan MF: Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg 2000, 232:362-371.
23. Middleton G, Cunningham D: Current options in the management of gastrointestinal cancer. Ann Oncol 1995, 6(Suppl 1):17-25.
24. Agboola O: Adjuvant treatment in gastric cancer. Cancer Treat Ref 1994, 20:217-240.
25. Gunderson LL, Sosin H: Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982, 8:1-11.
26. Gez E, Sulkes A, Peretz T, et al.: Combined 5-fluorouracil and radiation therapy following resection of locally advanced gastric carcinoma: a 5-year follow-up. Recent Results Cancer Res 1988, 110:52-56.
27. Moertel CG, Childs DS, O'Fallon JR, et al.: Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984, 2: 249-1254.
28. Bleiberg H, Goffin JC, Dalesio O, et al.: Adjuvant radiotherapy and chemotherapy in respectable gastric cancer: a randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC. Eur J Surg Oncol 1989, 15:535-543.
29. Yao JC, Ajani JA: Therapy of localized gastric cancer: preoperative and postoperative approaches. Ann Oncol 2002, 13(suppl 4):7-12.
30. Sautner T, Hofbauer F, Depisch D, et al.: Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994, 12:970-974.
31. Yu W, Whang I, Suh I, et al.: Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998, 228:347-354.
32. Rosen HR, Jatzko G, Repse S, et al.: Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998, 16:2733-2738.
33. Kelsen D, Karpeh M, Schwartz G, et al.: Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 1996, 14:1818-1828.
34. Newman E, Marcus SG, Potmesil M, et al.: Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer. J Gastrointest Surg 2002, 6:212-223.
35. Songun I, Keizer HJ, Hermans J, et al.: Chemotherapy for operable gastric cancer: results of the Dutch randomized FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer 1999, 35: 58-562.
36. Allum WH, Cunningham D, Weeden S: Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomized, controlled trial (the MAGIC trial, ISRCTN 93793971) [abstract 998]. Proc Am Soc Clin Oncol 2003, 22:249.
37. Ajani JA, Komaki R, Putnam JB, et al.: A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 2001, 92: 79-286.
38. Findlay M, Cunningham D, Norman A, et al.: A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF . Ann Oncol 1994, 5:609-616.
39. Webb A, Cunningham D, Scarffe JH, et al.: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997, 15:261-267.
40. Ajani JA, Van Cutsem E, Moiseyenko V, et al.: Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V325) [abstract 999]. Proc Am Soc Clin Oncol 2003, 22:249.
41. Imanaga H, Nakazato H: Results of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence. World J Surg 1977, 2:213-221.
42. Estape J, Grau JJ, Alcobendas F, et al.: Mitomycin C as an adjuvant treatment to resected gastric cancer: a 10-year follow-up. Ann Surg 1991, 213:219-221.
43. Grau JJ, Estape J, Alcobendas F, et al.: Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer 1993, 29A:340-342.
44. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group. Cancer 1982, 49:1116-1122.
45. Cirera L, Balil A, Batiste-Alentorn E, et al.: Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999, 17:3810-3815.
46. Grau JJ, Estape J, Fuster J, et al.: Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. J Clin Oncol, 1998, 16:1036-1039.
47. Neri B, Cini G, Andreoli F, et al.: Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer 2001, 84: 78-880.
48. Rougier P, Mahjoubi M, Lasser P, et al.: Neoadjuvant chemotherapy in locally advanced gastric carcinoma: a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer 1994, 30A:1269-1275.
49. Ajani JA, Mansfield PF, Ota DM: Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World J Surg 1995, 19:216-220.
50. Crookes P, Leichman CG, Leichman L, et al.: Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Cancer 1997, 79: 767-1775.
51. Ajani JA, Mansfield PF, Lynch PM, et al.: Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999, 17: 2403-2411.
52. Plukker JT, Mulder NH, Sleijfer DT, et al.: Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil. Br J Surg 1991, 78:955-958.
53. Ajani JA, Mayer RJ, Ota DM, et al.: Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 1993, 85:1839-1844.
54. Geh JI, Glynne-Jones R, Kwok QS, et al.: Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma. Clin Oncol (R Coll Radiol) 2000, 12:182-187.
55. Melcher AA, Mort D, Maughan TS: Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Br J Cancer 1996, 74:1651-1654.
56. Fink U, Schuhmacher C, Stein HJ, et al.: Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg 1995, 82:1248-1252.
57. Ajani JA, Ota DM, Jessup JM, et al.: Resectable gastric carcinoma: an evaluation of preoperative and postoperative chemotherapy. Cancer 1991, 68:1501-1506.
58. Menges M, Schmidt C, Lindemann W, et al.: Low toxic neoadjuvant cisplatin, 5-fluorouracil and folinic acid in locally advanced gastric cancer yields high R-0 resection rate. J Cancer Res Clin Oncol 2003, 129:423-429.
59. Yonemura Y, Sawa T, Kinoshita K, et al.: Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993, 17:256-262.